BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting
Abstract B-cell maturation antigen (BCMA) is currently the most extensively explored target for multiple myeloma (MM). BCMA-targeted therapies such as antibody-drug conjugate (ADC), bispecific antibodies (BsAbs), chimeric antigen receptor T(CAR-T) cell have shown promising therapeutic prospects in M...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13045-025-01675-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850238116767465472 |
|---|---|
| author | Huijian Zheng Huajian Xian Wenjie Zhang Chaoqun Lu Renyao Pan Han Liu Zhenshu Xu |
| author_facet | Huijian Zheng Huajian Xian Wenjie Zhang Chaoqun Lu Renyao Pan Han Liu Zhenshu Xu |
| author_sort | Huijian Zheng |
| collection | DOAJ |
| description | Abstract B-cell maturation antigen (BCMA) is currently the most extensively explored target for multiple myeloma (MM). BCMA-targeted therapies such as antibody-drug conjugate (ADC), bispecific antibodies (BsAbs), chimeric antigen receptor T(CAR-T) cell have shown promising therapeutic prospects in MM. We have summarized the latest reports on the three types of drugs for MM at the 2024 ASH Annual Meeting. |
| format | Article |
| id | doaj-art-037e45ce3b4142e0884e39c2707cfda0 |
| institution | OA Journals |
| issn | 1756-8722 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj-art-037e45ce3b4142e0884e39c2707cfda02025-08-20T02:01:34ZengBMCJournal of Hematology & Oncology1756-87222025-03-011811410.1186/s13045-025-01675-5BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meetingHuijian Zheng0Huajian Xian1Wenjie Zhang2Chaoqun Lu3Renyao Pan4Han Liu5Zhenshu Xu6Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union HospitalShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, National Research Center for Translational Medicine at Shanghai, Shanghai Jiao Tong University School of MedicineFujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union HospitalShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, National Research Center for Translational Medicine at Shanghai, Shanghai Jiao Tong University School of MedicineFujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union HospitalShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, National Research Center for Translational Medicine at Shanghai, Shanghai Jiao Tong University School of MedicineFujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union HospitalAbstract B-cell maturation antigen (BCMA) is currently the most extensively explored target for multiple myeloma (MM). BCMA-targeted therapies such as antibody-drug conjugate (ADC), bispecific antibodies (BsAbs), chimeric antigen receptor T(CAR-T) cell have shown promising therapeutic prospects in MM. We have summarized the latest reports on the three types of drugs for MM at the 2024 ASH Annual Meeting.https://doi.org/10.1186/s13045-025-01675-5BCMA-targeted therapiesMultiple myelomaASH 2024 |
| spellingShingle | Huijian Zheng Huajian Xian Wenjie Zhang Chaoqun Lu Renyao Pan Han Liu Zhenshu Xu BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting Journal of Hematology & Oncology BCMA-targeted therapies Multiple myeloma ASH 2024 |
| title | BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting |
| title_full | BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting |
| title_fullStr | BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting |
| title_full_unstemmed | BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting |
| title_short | BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting |
| title_sort | bcma targeted therapies for multiple myeloma latest updates from 2024 ash annual meeting |
| topic | BCMA-targeted therapies Multiple myeloma ASH 2024 |
| url | https://doi.org/10.1186/s13045-025-01675-5 |
| work_keys_str_mv | AT huijianzheng bcmatargetedtherapiesformultiplemyelomalatestupdatesfrom2024ashannualmeeting AT huajianxian bcmatargetedtherapiesformultiplemyelomalatestupdatesfrom2024ashannualmeeting AT wenjiezhang bcmatargetedtherapiesformultiplemyelomalatestupdatesfrom2024ashannualmeeting AT chaoqunlu bcmatargetedtherapiesformultiplemyelomalatestupdatesfrom2024ashannualmeeting AT renyaopan bcmatargetedtherapiesformultiplemyelomalatestupdatesfrom2024ashannualmeeting AT hanliu bcmatargetedtherapiesformultiplemyelomalatestupdatesfrom2024ashannualmeeting AT zhenshuxu bcmatargetedtherapiesformultiplemyelomalatestupdatesfrom2024ashannualmeeting |